Medical - Devices
Compare Stocks
2 / 10Stock Comparison
IRTC vs HOLX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
IRTC vs HOLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $4.10B | $16.97B |
| Revenue (TTM) | $788M | $4.13B |
| Net Income (TTM) | $-28M | $544M |
| Gross Margin | 71.0% | 52.8% |
| Operating Margin | -3.3% | 17.5% |
| Forward P/E | — | 17.2x |
| Total Debt | $731M | $2.63B |
| Cash & Equiv. | $236M | $1.96B |
IRTC vs HOLX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| iRhythm Technologie… (IRTC) | 100 | 100.5 | +0.5% |
| Hologic, Inc. (HOLX) | 100 | 142.6 | +42.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IRTC vs HOLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IRTC is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 26.2%, EPS growth 61.7%, 3Y rev CAGR 22.1%
- 379.3% 10Y total return vs HOLX's 124.3%
- 26.2% revenue growth vs HOLX's 1.7%
HOLX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.41
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
- Beta 0.41, current ratio 3.75x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 26.2% revenue growth vs HOLX's 1.7% | |
| Value | Better valuation composite | |
| Quality / Margins | 13.2% margin vs IRTC's -3.5% | |
| Stability / Safety | Beta 0.41 vs IRTC's 0.93, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +37.1% vs IRTC's -8.3% | |
| Efficiency (ROA) | 6.1% ROA vs IRTC's -2.8%, ROIC 9.4% vs -5.2% |
IRTC vs HOLX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
IRTC vs HOLX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — IRTC and HOLX each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HOLX is the larger business by revenue, generating $4.1B annually — 5.2x IRTC's $788M. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to IRTC's -3.5%. On growth, IRTC holds the edge at +25.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $788M | $4.1B |
| EBITDAEarnings before interest/tax | -$6M | $974M |
| Net IncomeAfter-tax profit | -$28M | $544M |
| Free Cash FlowCash after capex | $19M | $1000M |
| Gross MarginGross profit ÷ Revenue | +71.0% | +52.8% |
| Operating MarginEBIT ÷ Revenue | -3.3% | +17.5% |
| Net MarginNet income ÷ Revenue | -3.5% | +13.2% |
| FCF MarginFCF ÷ Revenue | +2.4% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +25.7% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +55.7% | -9.2% |
Valuation Metrics
HOLX leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $4.1B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $4.6B | $17.6B |
| Trailing P/EPrice ÷ TTM EPS | -89.83x | 30.53x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 17.39x |
| Price / SalesMarket cap ÷ Revenue | 5.49x | 4.14x |
| Price / BookPrice ÷ Book value/share | 26.16x | 3.43x |
| Price / FCFMarket cap ÷ FCF | 118.84x | 18.44x |
Profitability & Efficiency
HOLX leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
HOLX delivers a 11.0% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-21 for IRTC. HOLX carries lower financial leverage with a 0.52x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRTC's 4.79x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs IRTC's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -20.6% | +11.0% |
| ROA (TTM)Return on assets | -2.8% | +6.1% |
| ROICReturn on invested capital | -5.2% | +9.4% |
| ROCEReturn on capital employed | -4.4% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 |
| Debt / EquityFinancial leverage | 4.79x | 0.52x |
| Net DebtTotal debt minus cash | $495M | $667M |
| Cash & Equiv.Liquid assets | $236M | $2.0B |
| Total DebtShort + long-term debt | $731M | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | -1.48x | 8.00x |
Total Returns (Dividends Reinvested)
IRTC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IRTC five years ago would be worth $15,609 today (with dividends reinvested), compared to $11,582 for HOLX. Over the past 12 months, HOLX leads with a +37.1% total return vs IRTC's -8.3%. The 3-year compound annual growth rate (CAGR) favors IRTC at -0.7% vs HOLX's -2.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -28.7% | +1.9% |
| 1-Year ReturnPast 12 months | -8.3% | +37.1% |
| 3-Year ReturnCumulative with dividends | -2.1% | -8.5% |
| 5-Year ReturnCumulative with dividends | +56.1% | +15.8% |
| 10-Year ReturnCumulative with dividends | +379.3% | +124.3% |
| CAGR (3Y)Annualised 3-year return | -0.7% | -2.9% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than IRTC's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs IRTC's 58.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.93x | 0.41x |
| 52-Week HighHighest price in past year | $212.00 | $76.04 |
| 52-Week LowLowest price in past year | $112.31 | $52.81 |
| % of 52W HighCurrent price vs 52-week peak | +58.9% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 44.1 | 69.1 |
| Avg Volume (50D)Average daily shares traded | 524K | 10.0M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates IRTC as "Buy" and HOLX as "Hold". Consensus price targets imply 55.1% upside for IRTC (target: $194) vs 3.9% for HOLX (target: $79).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $193.67 | $79.00 |
| # AnalystsCovering analysts | 19 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.4% |
HOLX leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). IRTC leads in 1 (Total Returns). 1 tied.
IRTC vs HOLX: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is IRTC or HOLX a better buy right now?
For growth investors, iRhythm Technologies, Inc.
(IRTC) is the stronger pick with 26. 2% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate iRhythm Technologies, Inc. (IRTC) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IRTC or HOLX?
Over the past 5 years, iRhythm Technologies, Inc.
(IRTC) delivered a total return of +56. 1%, compared to +15. 8% for Hologic, Inc. (HOLX). Over 10 years, the gap is even starker: IRTC returned +379. 3% versus HOLX's +124. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IRTC or HOLX?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus iRhythm Technologies, Inc. 's 0. 93β — meaning IRTC is approximately 127% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 5% for iRhythm Technologies, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — IRTC or HOLX?
By revenue growth (latest reported year), iRhythm Technologies, Inc.
(IRTC) is pulling ahead at 26. 2% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: iRhythm Technologies, Inc. grew EPS 61. 7% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, IRTC leads at 22. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IRTC or HOLX?
Hologic, Inc.
(HOLX) is the more profitable company, earning 13. 8% net margin versus -6. 0% for iRhythm Technologies, Inc. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -4. 9% for IRTC. At the gross margin level — before operating expenses — IRTC leads at 70. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is IRTC or HOLX more undervalued right now?
Analyst consensus price targets imply the most upside for IRTC: 55.
1% to $193. 67.
07Which pays a better dividend — IRTC or HOLX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is IRTC or HOLX better for a retirement portfolio?
For long-horizon retirement investors, Hologic, Inc.
(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). Both have compounded well over 10 years (HOLX: +124. 3%, IRTC: +379. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between IRTC and HOLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: IRTC is a small-cap high-growth stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.